Steady state expression of cell-cycle regulatory genes in prostate carcinoma cell lines

Urologic Oncology

Volumn 5, Issue 2, 2000, Pages 71-77

  McGarvey, Terence W ^a   Malkowicz, S Bruce ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Cdk inhibitors; Cell cycle; Prostate carcinoma; Transforming growth factor (TGF )

Indexed keywords

CYCLINE; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR;

ARTICLE; CANCER CELL CULTURE; CARCINOGENESIS; CELL CYCLE; CONTROLLED STUDY; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROSTATE; PROSTATE CARCINOMA; REGULATOR GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STEADY STATE;

EID: 0033990207     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1078-1439(99)00003-4     Document Type: Article

References (51)

1. Brown C., Sauvageot J., Kahane H., Epstein J.I. Cell proliferation and apoptosis in prostate-correlation with pathologic stage? Mod Path. 9:1996;205-209.
2. Stattin P., Damber J.E., Karlberg L., Bergh A. Cell proliferation assessed by Ki-67 immunoreactivity on formalin fixed tissues is a predictive factor of survival in prostate cancer. J Urol. 157:1997;219-222.
3. 1 to S phase transition. Ann Rev Cell Biol. 8:1992;529-531.
4. 1 cyclins. Cell. 73:1993;1059-1065.
5. Ewen M.E., Sluss H.K., Whitehouse L.L., Livingston D.M. TGF-β inhibition of Cdk4 synthesis is linked to cell cycle arrest. Cell. 74:1993;1009-1020.
6. 1 cyclins and cyclin-dependent protein kinases. Proc Natl Acad Sci USA. 90:1993;10315-10319.
7. Gotoh A., Kao C., Ko S.C., Hamada K., Liu T.J., Chung L.W. Cytotoxic effects of recombinant adenovirus p53 and cell cycle regulator genes (p21 WAF1/CIP1 and p16CDKN4) in human prostate cancers. J Urol. 158:1997;636-641.
8. Knabbe C., Klein H., Zugmaier G., Voigt K.D. Hormonal regulation of transforming growth factor β-2 expression in human prostate cancer. J Steroid Biochem Mol Biol. 47:1993;137-142.
9. Wilding G., Zugmaier G., Knabbe C. Differential effects of TGF-β on human prostate cancer cells in vitro. Mol Cell Endocrinol. 62:1989;79-87.
10. Carruba G., Pfeffer U., Fecarotta E.et al. Estradiol inhibits growth of hormone-nonresponsive PC-3 human prostate cancer cells. Cancer Res. 54:1994;1190-1193.
11. Djonov V., Ball R.K., Graf S.et al. Transforming growth factor-β3 is expressed in nondividing basal epithelial cells in normal human prostate and benign prostate hyperplasia and is no longer detectable in prostate carcinoma. Prostate. 31:1997;103-109.
12. Merz V.W., Arnold A.M., Studer U.E. Differential expression of transforming growth β-1 and β3 as well as C-FOS mRNA in normal prostate, benign prostatic hyperplasia and prostatic cancer. World J Urology. 12:1994;96-98.
13. El-Deiry W.S., Tokino T., Velculescu V.E.et al. WAF1, a potential mediator of p53 tumor suppression. Cell. 75:1993;817-825.
14. 1 cyclin-dependent kinases. Cell. 75:1993;805-816.
15. Prelich G., Stillman B. Coordinated leading and lagging strand synthesis during SV40 DNA replication in vitro requires PCNA. Cell. 53:1988;117-126.
16. Shivji M.K.K., Kenny M.K., Wood R.D. PCNA is required for DNA excision repair. Cell. 69:1992;367-374.
17. Waga S., Hannon G.J., Beach D., Stillman B. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature. 369:1994;574-578.
18. Bookstein R., MacGrogan D., Hisenbeck S.G. p53 is mutated in a subset of advanced-stage prostate cancers. Cancer Res. 53:1993;3369-3373.
19. Navone N.M., Troncoso P., Pisters L.L. p53 is mutated in a subset of advanced-stage prostate cancers. Cancer Res. 53:1993;3369-3373.
20. Datto M.B., Li Y., Panus J.F., Howe D.J., Xiong Y., Wang X.-F. Transforming growth factor-β induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism. Proc Natl Acad Sci USA. 92:1995;5545-5549.
21. Jiang H., Lin J., Su Z.-Z., Collart F., Huberman E., Fisher P.B. Induction of differentiation in human promyelocytic HL-60 leukemia cells activates p21, WAF1/CIP1, expression in the absence of p53. Oncogene. 9:1994;3397-3406.
22. Michieli P., Chedid M., Lin D., Piece J.H., Mercer W.E., Givoi D. Induction of WAF1/CIP1 by a p53-independent pathway. Cancer Res. 54:1994;3391-3395.
23. Sheikh M.S., Li X.-S., Chen J.-C., Shao Z.-M., Ordonez J.V., Fontana J.A. Mechanisms of regulation of gene expression in human breast carcinoma. role of p53-dependent and independent signal transduction pathways Oncogene. 9:1994;3407-3415.
24. ink4B is a potential effector of TGF-B-induced cell cycle arrest. Nature. 371:1994;257-261.
25. Kato J., Matsuoka M., Polyak K., Massague J., Sherr C.J. Cyclic AMP-induced G1 phase arrest mediated by an inhibitor (p27KIP1) of cyclin-dependent kinase 4 activation. Cell. 79:1994;487-496.
26. Kip1, a cyclin-Cdk inhibitor, link TGF-β and contact inhibition to cell cycle arrest. Genes Devel. 8:1994;9-22.
27. Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 162:1987;156-159.
28. Chomczynski P. A reagent for the simple-step simultaneous isolation of RNA, DNA and proteins from cell and tissue samples. Biotechniques. 15:1993;532-536.
29. Horikoshi T., Danenberg K., Volkenandt M., Stadlbauer T., Danenberg P.V. Quantitative measurement of relative gene expression in human tumors. PCR protocols, current methods and applications. Methods Mol Biol. 15:1993;177-188.
30. Seshadri T., Uzman J.A., Oshima J., Campisi J. Identification of a transcript that is down regulated in senescent human fibroblasts. cloning, sequence analysis and regulation of the human L7 ribosomal protein gene J Biol Chem. 268:1993;18474-18480.
31. Strowronski R.J., Peehl D.M., Feldman D. Vitamin D and prostate cancer. 1,25 dihydroxyvitamin D3 receptors and actions in human prostate cell lines Endocrinology. 132:1993;1952-1960.
32. Issacs W.B., Carter B.S., Ewing C.M. Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles. Cancer Res. 51:1991;4716-4720.
33. Hobeika A.C., Subramaniam P.S., Johnson H.M. INFalpha induces the expression of the cyclin-dependent kinase inhibitor p21 in human prostate cancer cells. Oncogene. 14:1997;165-170.
34. WAF1/CIP1 by retinoic acid receptor. J Biol Chem. 271:1996;31723-31728.
35. (WAF1/CIP1) expression through mitogen-activated protein kinase signaling pathway. Cancer Res. 56:1996;31-35.
36. Carroll A.G., Voeller H.J., Sugars L., Gelmann E.P. p53 oncogene mutations in three human prostate cancer cell lines. Prostate. 23:1993;123-134.
37. WAF1. Cancer Res. 55:1995;4536-4539.
38. KIP1 protein in human prostate cancer correlates with tumor grade. Clin Cancer Res. 3:1997;2269-2274.
39. Pagano M., Tam S.W., Theodoras A.M.et al. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science. 269:1995;682-685.
40. 1 arrest in prostatic cancer cell line DU145. Cancer Res. 56:1996;3666-3669.
41. Markowitz S., Wang J., Myeroff L.et al. Inactivation of the type II TGF-β receptor in colon cancer cells with microsatellite instability. Science. 268:1995;1336-1338.
42. Okamoto A., Jiang W., Kim S.-J.et al. Overexpression of human cyclin D1 reduces the transforming growth factor β (TGF-β) type II receptor and growth inhibition by TGF-β1 in an immortalized human esophageal epithelial cell line. Proc Natl Acad Sci USA. 91:1994;11576-11580.
43. Cunningham J.M., Shan W., Aick M.J.et al. Allelic imbalance and microsatellite instability in prostatic adenocarcinoma. Cancer Res. 56:1996;4475-4482.
44. Chen Y., Navone N.M., Conti C.J. Expression of cyclin D1 in human prostate cancer cell lines. Urol Oncol. 1:1995;101-108.
45. Williams R.H., Stapleton A.M.F., Yang G. Reduced levels of transforming growth factor β receptor type II in human prostate cancer. an immunohistochemical study Clin Cancer Res. 2:1996;635-640.
46. Kim I.Y., Ahn H.-Y., Zelner D.J.et al. Genetic change in transforming growth factor β (TGF-β) receptor type I gene correlates with insensitivity to TGF-β1 in human prostatic cancer cells. Cancer Res. 56:1996;44-48.
47. Khatib Z.A., Matsushime H., Valentine M., Shapiro D.N., Sherr C.J., Look A.T. Coamplification of the Cdk-4 gene with MDM2 and GLI in human sarcomas. Cancer Res. 53:1993;5535-5541.
48. Reifenberger G., Reifenberger J., Ichimura K., Meltzer P.S., Collins V.P. Amplification of multiple genes from chromosomal region 12q13-14 in human malignant glioma. preliminary mapping of the amplicons shows preferential involvement of Cdk-4, SAS and MDM2 Cancer Res. 54:1994;4299-4303.
49. Buckley M.F., Sweeney J.E., Hamilton J.A.et al. Expression and amplification of cyclin genes in human breast cancer. Oncogene. 8:1993;2127-2133.
50. Keyomarsi K., Conte D., Toyofuku W., Fox M.P. Deregulation of cyclin E in breast cancer. Oncogene. 11:1995;941-950.
51. Porter P.L., Malone K.E., Heagerty P.J.et al. Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with young breast cancer patients. Nature Medicine. 3:1997;222-225.